Sichuan Kelun-Biotech Biopharmaceutical's (HKG:6990, SHE:002422) partner Windward Bio reported positive interim results from phase 2 of the POLARIS-1 clinical trial of SKB378/WIN378.
The drug targets thymic stromal lymphopoietin in asthma, according to a Tuesday Hong Kong bourse filing.
According to the results, the drug was well tolerated, with favorable safety results and no treatment-related serious adverse events, withdrawals, or discontinuations.
Phase 3 of the trial has commenced.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.